News | Artificial Intelligence | December 27, 2019

Artificial Intelligence Identifies Previously Unknown Features Associated with Cancer Recurrence

The AI also identified features relevant to cancer prognosis that were not previously noted by pathologists, leading to a higher accuracy of prostate cancer recurrence compared to pathologist-based diagnosis

The AIP's RAIDEN AI supercomputer

The AIP's RAIDEN AI supercomputer

December 27, 2019 — Artificial intelligence (AI) technology developed by the RIKEN Center for Advanced Intelligence Project (AIP) in Japan has successfully found features in pathology images from human cancer patients, without annotation, that could be understood by human doctors. Further, the AI identified features relevant to cancer prognosis that were not previously noted by pathologists, leading to a higher accuracy of prostate cancer recurrence compared to pathologist-based diagnosis. Combining the predictions made by the AI with predictions by human pathologists led to an even greater accuracy.

According to Yoichiro Yamamoto, M.D., Ph.D., the first author of the study published in Nature Communications, "This technology could contribute to personalized medicine by making highly accurate prediction of cancer recurrence possible by acquiring new knowledge from images. It could also contribute to understanding how AI can be used safely in medicine by helping to resolve the issue of AI being seen as a 'black box.'"

The research group led by Yamamoto and Go Kimura, in collaboration with a number of university hospitals in Japan, adopted an approach called "unsupervised learning." As long as humans teach the AI, it is not possible to acquire knowledge beyond what is currently known. Rather than being "taught" medical knowledge, the AI was asked to learn using unsupervised deep neural networks, known as autoencoders, without being given any medical knowledge. The researchers developed a method for translating the features found by the AI — only numbers initially — into high-resolution images that can be understood by humans.

To perform this feat the group acquired 13,188 whole-mount pathology slide images of the prostate from Nippon Medical School Hospital (NMSH), The amount of data was enormous, equivalent to approximately 86 billion image patches (sub-images divided for deep neural networks), and the computation was performed on AIP's powerful RAIDEN supercomputer.

The AI learned using pathology images without diagnostic annotation from 11 million image patches. Features found by AI included cancer diagnostic criteria that have been used worldwide, on the Gleason score, but also features involving the stroma — connective tissues supporting an organ — in non-cancer areas that experts were not aware of. In order to evaluate these AI-found features, the research group verified the performance of recurrence prediction using the remaining cases from NMSH (internal validation). The group found that the features discovered by the AI were more accurate (AUC=0.820) than predictions made based on the human-established cancer criteria developed by pathologists, the Gleason score (AUC=0.744). Furthermore, combining both AI-found features and the human-established criteria predicted the recurrence more accurately than using either method alone (AUC=0.842). The group confirmed the results using another dataset including 2,276 whole-mount pathology images (10 billion image patches) from St. Marianna University Hospital and Aichi Medical University Hospital (external validation).

"I was very happy," said Yamamoto, "to discover that the AI was able to identify cancer on its own from unannotated pathology images. I was extremely surprised to see that AI found features that can be used to predict recurrence that pathologists had not identified."

He continued, "We have shown that AI can automatically acquire human-understandable knowledge from diagnostic annotation-free histopathology images. This 'newborn' knowledge could be useful for patients by allowing highly-accurate predictions of cancer recurrence. What is very nice is that we found that combining the AI's predictions with those of a pathologist increased the accuracy even further, showing that AI can be used hand-in-hand with doctors to improve medical care. In addition, the AI can be used as a tool to discover characteristics of diseases that have not been noted so far, and since it does not require human knowledge, it could be used in other fields outside medicine."

For more information: www.riken.jp/en/research/labs/aip/

Related Content

he U.S. Food and Drug Administration (FDA) has issued a final order to reclassify medical image analyzers applied to mammography breast cancer, ultrasound breast lesions, radiograph lung nodules and radiograph dental caries detection, postamendments class III devices (regulated under product code MYN), into class II (special controls), subject to premarket notification

Image courtesy of iCAD

News | Computer-Aided Detection Software | January 22, 2020
January 22, 2020 — The U.S.
Medical imaging technology company Oxipit announced partnership with Swiss medical distribution company Healthcare Konnect to bring ChestEye AI imaging suite to healthcare institutions in Nigeria
News | Artificial Intelligence | January 22, 2020
January 22, 2020 — Medical imaging technology company Oxipit ann
Hitachi Healthcare Americas announced that it will create a new dedicated research and development facility within its North American headquarters facility in Twinsburg, Ohio
News | Radiology Business | January 21, 2020
January 21, 2020 — Hitachi Healthcare Americas announced that it will create a new dedicated research and development
Virtual reality during chemotherapy has been shown to improve breast cancer patients’ quality of life during the most stressful treatments
News | Virtual and Augmented Reality | January 21, 2020
January 21, 2020 — Virtual reality during chemotherapy has been shown to improve...
This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.   #RSNA #

This is a lung X-ray reviewed automatically by artificial intelligence (AI) to identify a collapsed lung (pneumothorax) in the color coded area. This AI app from Lunit is awaiting final FDA review and in planned to be integrated into several vendors' mobile digital radiography (DR) systems. Fujifilm showed this software integrated as a work-in-progress into its mobile X-ray system at RSNA 2019. GE Healthcare has its own version of this software for its mobile r=ray systems that gained FDA in 2019.

Feature | RSNA | January 20, 2020 | Dave Fornell, Editor
Here are images of some of the newest new medical imaging technologies displayed on the expo floor at the ...
Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Videos | RSNA | January 13, 2020
ITN Editor Dave Fornell takes a tour of some of the most innovative new medical imaging technologies displayed on the
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined